L-Carnitine in Omnivorous Diets Induces an Atherogenic Gut Microbial Pathway in Humans
Overview
Authors
Affiliations
Background: l-Carnitine, an abundant nutrient in red meat, accelerates atherosclerosis in mice via gut microbiota-dependent formation of trimethylamine (TMA) and trimethylamine N-oxide (TMAO) via a multistep pathway involving an atherogenic intermediate, γ-butyrobetaine (γBB). The contribution of γBB in gut microbiota-dependent l-carnitine metabolism in humans is unknown.
Methods: Omnivores and vegans/vegetarians ingested deuterium-labeled l-carnitine (d3-l-carnitine) or γBB (d9-γBB), and both plasma metabolites and fecal polymicrobial transformations were examined at baseline, following oral antibiotics, or following chronic (≥2 months) l-carnitine supplementation. Human fecal commensals capable of performing each step of the l-carnitine→γBB→TMA transformation were identified.
Results: Studies with oral d3-l-carnitine or d9-γBB before versus after antibiotic exposure revealed gut microbiota contribution to the initial 2 steps in a metaorganismal l-carnitine→γBB→TMA→TMAO pathway in subjects. Moreover, a striking increase in d3-TMAO generation was observed in omnivores over vegans/vegetarians (>20-fold; P = 0.001) following oral d3-l-carnitine ingestion, whereas fasting endogenous plasma l-carnitine and γBB levels were similar in vegans/vegetarians (n = 32) versus omnivores (n = 40). Fecal metabolic transformation studies, and oral isotope tracer studies before versus after chronic l-carnitine supplementation, revealed that omnivores and vegans/vegetarians alike rapidly converted carnitine to γBB, whereas the second gut microbial transformation, γBB→TMA, was diet inducible (l-carnitine, omnivorous). Extensive anaerobic subculturing of human feces identified no single commensal capable of l-carnitine→TMA transformation, multiple community members that converted l-carnitine to γBB, and only 1 Clostridiales bacterium, Emergencia timonensis, that converted γBB to TMA. In coculture, E. timonensis promoted the complete l-carnitine→TMA transformation.
Conclusion: In humans, dietary l-carnitine is converted into the atherosclerosis- and thrombosis-promoting metabolite TMAO via 2 sequential gut microbiota-dependent transformations: (a) initial rapid generation of the atherogenic intermediate γBB, followed by (b) transformation into TMA via low-abundance microbiota in omnivores, and to a markedly lower extent, in vegans/vegetarians. Gut microbiota γBB→TMA/TMAO transformation is induced by omnivorous dietary patterns and chronic l-carnitine exposure.
Trial Registration: ClinicalTrials.gov NCT01731236.
Funding: NIH and Office of Dietary Supplements grants HL103866, HL126827, and DK106000, and the Leducq Foundation.
Lin X, Yu Z, Liu Y, Li C, Hu H, Hu J Imeta. 2025; 4(1):e270.
PMID: 40027477 PMC: 11865426. DOI: 10.1002/imt2.270.
Zheng X, Fan J, Yin J, Chu Y Medicine (Baltimore). 2025; 104(9):e41710.
PMID: 40020117 PMC: 11875619. DOI: 10.1097/MD.0000000000041710.
γBMGC: A Comprehensive and Accurate Database for Screening TMAO-Associated Cardiovascular Diseases.
Yang G, Tao T, Yu G, Zhang H, Wu Y, Sun S Microorganisms. 2025; 13(2).
PMID: 40005591 PMC: 11857547. DOI: 10.3390/microorganisms13020225.
Current Therapeutic Landscape for Metabolic Dysfunction-Associated Steatohepatitis.
Devasia A, Ramasamy A, Leo C Int J Mol Sci. 2025; 26(4).
PMID: 40004240 PMC: 11855529. DOI: 10.3390/ijms26041778.
Li X, Wang Y, Xu J, Luo K, Dong T Front Cardiovasc Med. 2024; 11:1334730.
PMID: 39720206 PMC: 11666687. DOI: 10.3389/fcvm.2024.1334730.